Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia

Documenti analoghi

• Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia
  di: Zugmaier, G, et al.
  Pubblicazione: (2014)
• Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment
  di: Zugmaier, Gerhard, et al.
  Pubblicazione: (2015)
• Long‐term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab
  di: Topp, Max S., et al.
  Pubblicazione: (2020)
• Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
  di: Gökbuget, Nicola, et al.
  Pubblicazione: (2018)
• Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia
  di: Topp, M S, et al.
  Pubblicazione: (2018)